ESALF Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 апр. 2024 @ 20:54):

Stats
Объем за сегодня	4.00
Средний объем	1 120.00
Рыночная капитализация	11.48B
EPS	$9.72 ( 2023-11-06 )
Last Dividend	$0.603 ( 2023-03-30 )
Next Dividend	$0 ( N/A )
P/E	39.22
ATR14	$0 (0.00%)

Eisai Co., Ltd. Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Eisai Co., Ltd. Финансовые показатели

Annual	2023
Выручка:	$744.40B
Валовая прибыль:	$543.48B (73.01 %)
EPS:	$193.31

FY	2023
Выручка:	$744.40B
Валовая прибыль:	$543.48B (73.01 %)
EPS:	$193.31

FY	2022
Выручка:	$756.23B
Валовая прибыль:	$569.79B (75.35 %)
EPS:	$167.27

FY	2021
Выручка:	$645.94B
Валовая прибыль:	$484.63B (75.03 %)
EPS:	$146.95

Financial Reports:

No articles found.

Eisai Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.555 (N/A)	$0 (N/A)	$0.603 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Eisai Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.00 - Decrease likely (20.04%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.784	2014-03-27
Last Dividend	$0.603	2023-03-30
Next Dividend	$0	N/A
Payout Date	2018-05-24
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	$11.60	--
Avg. Dividend % Per Year	0.00%	--
Score	2.79	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.00
Div. Directional Score	7.04	--

Next Divdend (Est)
(2024-09-23)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

2.79

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
RNMBY	Ex Dividend Knight	2023-05-10	Annually	0.00%
FFDF	Ex Dividend Knight	2023-08-01	Quarterly	0.00%
WBHC	Ex Dividend Junior	2023-06-29	Sporadic	0.00%
LYBC	Ex Dividend Knight	2023-09-28	Quarterly	0.00%
CLLNY	Ex Dividend Junior	2023-06-16	Semi-Annually	0.00%
SLVYY	Ex Dividend Knight	2023-05-15	Semi-Annually	0.00%
HALMY	Ex Dividend Knight	2023-07-14	Semi-Annually	0.00%
AMADY	Ex Dividend Knight	2023-07-11	Annually	0.00%
NDBKY	Ex Dividend Junior	2023-09-07	Annually	0.00%
CRZBY	Ex Dividend Junior	2023-06-01	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0606	1.500	8.79	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0346	1.200	8.85	10.00	[0 - 0.3]
returnOnEquityTTM	0.0546	1.500	-0.504	-0.756	[0.1 - 1]
payoutRatioTTM	1.011	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	2.38	0.800	3.10	2.48	[1 - 3]
quickRatioTTM	1.697	0.800	4.72	3.78	[0.8 - 2.5]
cashRatioTTM	1.025	1.500	5.42	8.12	[0.2 - 2]
debtRatioTTM	0.127	-1.500	7.89	-10.00	[0 - 0.6]
interestCoverageTTM	25.36	1.000	1.719	1.719	[3 - 30]
operatingCashFlowPerShareTTM	215.91	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	166.26	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.203	-1.500	9.19	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.789	1.000	0.176	0.176	[0.2 - 0.8]
operatingProfitMarginTTM	0.0790	1.000	-0.419	-0.419	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.372	1.000	9.04	9.04	[0.2 - 2]
assetTurnoverTTM	0.572	0.800	9.52	7.62	[0.5 - 2]
Total Score				10.08

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	39.99	1.000	6.06	0	[1 - 100]
returnOnEquityTTM	0.0546	2.50	-0.324	-0.756	[0.1 - 1.5]
freeCashFlowPerShareTTM	166.26	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0168	1.500	9.58	0	[0 - 0.4]
operatingCashFlowPerShareTTM	215.91	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	1.011	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.0162	1.500	-3.23	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0826	1.000	-0.434	0	[0.1 - 0.5]
Total Score				4.00

Eisai Co., Ltd.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.